NIH launches clinical trial of universal influenza vaccine candidate

(NIH/National Institute of Allergy and Infectious Diseases) A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun. Healthy participants 18 to 50 years old will receive either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1. Scientists from NIAID developed FluMos-v1 to stimulate antibodies against multiple influenza virus strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news